Login to Your Account

Thanks, but 'Lpath': AMD phase II bust dents stock, staff cuts to fund new bid

By Randy Osborne
Staff Writer

Wednesday, May 20, 2015
Lpath Inc.'s stock plunged 79.5 percent on word of the lead compound's phase II blowup, but "there exists some true assets that can be built upon," spokeswoman Pam Lord told BioWorld Today, and the company is restructuring to conserve money.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription